CHMP recommends extending use of Tamiflu (oseltamivir) to infants with influenza- Roche

The EU's CHMP has recommended extending the use of Roche’s Tamiflu (oseltamivir) to include the treatment of influenza in infants below one year of age. Efficacy has been demonstrated when treatment is initiated within two days of onset of symptoms. Tamiflu was previously approved in the EU for patients aged at least one year.